Screener
LB Pharmaceuticals Inc LBRX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $14,645 | $3,421 |
| General and administrative | 7,459 | 3,008 |
| Total operating loss | (22,104) | (6,429) |
| Non-operating income | ||
| Interest income | 2,850 | 236 |
| Realized gain on sale of marketable securities, net | — | 119 |
| Gain on change in fair value of derivative instruments | 200 | 768 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's other operating expenses?
- LB Pharmaceuticals Inc (LBRX) reported other operating expenses of $22.1M in Q1 2026.
- How has LB Pharmaceuticals Inc's other operating expenses changed year-over-year?
- LB Pharmaceuticals Inc's other operating expenses increased by 243.8% year-over-year, from $6.43M to $22.1M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about LB Pharmaceuticals Inc's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude